Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (9196)	9/24/2003 9:25:43 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

John, I suspect a good part of what's happening here is the FDA struggling with what is the best test to use for severe AD patients. It might well be that the MME is not very sensitive or reliable when the patients are advanced. Here is a description of the MME: alzheimers.org.uk Note that if memantine is indeed not working for the advanced patients it implies it must be having a dramatic effect on the moderate patients. But from what I can tell it looks like it does work for advanced patients - just not for their scores on the MME. You make a very valid point - you can easily get improvement (like your mom remembering your name) that isn't captured by a simplistic test like the MME. Peter